{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:59:18Z","timestamp":1794967158415,"version":"4.9.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,5]],"date-time":"2027-02-05T00:00:00Z","timestamp":1801785600000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.autrev.2025.103962","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:41:21Z","timestamp":1764117681000},"page":"103962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Autoantibody internalization in myositis skeletal muscle: Emerging evidence, mechanistic insights, and therapeutic relevance"],"prefix":"10.1016","volume":"25","author":[{"given":"Raphael A.","family":"Kirou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Pinal-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103962_bb0005","doi-asserted-by":"crossref","unstructured":"M. Casal-Dominguez, I. Pinal-Fernandez, K. Pak, W. Huang, A. Selva-O'Callaghan, J. Albayda, L. Casciola-Rosen, J.J. Paik, E. Tiniakou, C.A. Mecoli, T.E. Lloyd, S.K. Danoff, L. Christopher-Stine and A.L. Mammen, Performance of the 2017 European Alliance of associations for rheumatology\/American College of Rheumatology Classification Criteria for idiopathic inflammatory myopathies in patients with myositis-specific autoantibodies, Arthritis Rheumatol 74 (2022) 508\u2013517.","DOI":"10.1002\/art.41964"},{"key":"10.1016\/j.autrev.2025.103962_bb0010","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103962_bb0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0020","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103962_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113454","article-title":"Efficacy and safety of high-dose immunoglobulin-based regimen in statin-associated autoimmune myopathy: a multi-center and multi-disciplinary retrospective study","volume":"9","author":"Treppo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103962_bb0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103962_bb0035","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103962_bb0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2500\/aap.2019.40.4274","article-title":"Classification of hypersensitivity reactions","volume":"40","author":"Dispenza","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.autrev.2025.103962_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/271067a0","article-title":"Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors","volume":"271","author":"Alarcon-Segovia","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103962_bb0050","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0055","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103962_bb0060","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1093\/rheumatology\/keaf346","article-title":"Distinct cytokine and cytokine receptor expression patterns characterize different forms of myositis","volume":"64","author":"Kirou","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103962_bb0065","doi-asserted-by":"crossref","DOI":"10.1101\/2025.03.04.25323364","article-title":"Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1gamma, while anti-TIF1gamma autoantibodies primarily bind TIF1gamma outside the PHD region","author":"Pinal-Fernandez","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103962_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.08.023","article-title":"Myositis-specific autoantibodies recognizing Mi2 also target the autoimmune regulator (AIRE) protein at a shared PHD-zinc finger","author":"Musai","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0075","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/ard-2023-223873","article-title":"Transcriptional derepression of CHD4\/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0080","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/rheumatology\/kead400","article-title":"Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains","volume":"63","author":"Van Gompel","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103962_bb0085","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/kead550","article-title":"Correlation between B-cell epitope profile and clinical features of anti-MDA5 antibody-positive dermatomyositis","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103962_bb0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","article-title":"A balancing act: MDA5 in antiviral immunity and autoinflammation","volume":"27","author":"Dias Junior","year":"2019","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.autrev.2025.103962_bb0095","article-title":"RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-alpha","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0100","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103962_bb0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2025.103962_bb0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2313070121","article-title":"Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice","volume":"121","author":"Ichimura","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103962_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12931-023-02362-0","article-title":"Enhanced immune complex formation in the lungs of patients with dermatomyositis","volume":"24","author":"Zaizen","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.autrev.2025.103962_bb0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41586-021-04054-5","article-title":"Self-guarding of MORC3 enables virulence factor-triggered immunity","volume":"600","author":"Gaidt","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103962_bb0125","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.1038\/ncomms9900","article-title":"TRIM33 switches off Ifnb1 gene transcription during the late phase of macrophage activation","volume":"6","author":"Ferri","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103962_bb0130","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","article-title":"Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1gamma can result in experimental myositis","volume":"80","author":"Okiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103962_bb0140","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.ard.2025.04.027","article-title":"In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis","volume":"84","author":"Giannini","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Clinical Research, Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2025.103962_bb0150","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103962_bb0155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0160","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1093\/emboj\/cdg337","article-title":"Structure, function and evolution of the signal recognition particle","volume":"22","author":"Nagai","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.autrev.2025.103962_bb0165","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200116","article-title":"Jo-1 antibodies from myositis induce complement-dependent cytotoxicity and TREM-1 upregulation in muscle endothelial cells","volume":"10","author":"Honda","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103962_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1525","article-title":"Anti-signal recognition particle antibodies induce cardiac diastolic dysfunction via oxidative stress injury","volume":"13","author":"Zhang","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0175","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","article-title":"Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial","volume":"5","author":"Mammen","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103962_bb0180","article-title":"Antisynthetase autoantibodies disrupt the function of their target aminoacyl-tRNA Synthetases in muscle cells [abstract]","volume":"76","author":"Casal-Dominguez","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103962_bb0185","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis-specific antibodies: novel and classical biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrm.2015.15","article-title":"The regulation and functions of the nuclear RNA exosome complex","volume":"17","author":"Kilchert","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.autrev.2025.103962_bb0195","first-page":"364","article-title":"Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic lupus erythematosus","volume":"35","author":"Alarcon-Segovia","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0200","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1523-1747.ep12526097","article-title":"In vitro study of the binding of antiribonucleoprotein antibodies to the nucleus of isolated living keratinocytes","volume":"76","author":"Galoppin","year":"1981","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103962_bb0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2249.1991.tb08128.x","article-title":"Antibody penetration of viable human cells. I. Increased penetration of human lymphocytes by anti-RNP IgG","volume":"84","author":"Ma","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0210","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2249.1993.tb08191.x","article-title":"Antibody penetration of viable human cells. II. Anti-RNP antibodies binding to RNP antigen expressed on cell surface, which may mediate the antibody internalization","volume":"93","author":"Ma","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0090-1229(82)90067-8","article-title":"Antibody penetration into living cells. III. Effect of antiribonucleoprotein IgG on the cell cycle of human peripheral blood mononuclear cells","volume":"23","author":"Alarcon-Segovia","year":"1982","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.autrev.2025.103962_bb0220","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4049\/jimmunol.122.5.1855","article-title":"Antibody penetration into living cells. II. Anti-ribonucleoprotein IgG penetrates into Tgamma lymphocytes causing their deletion and the abrogation of suppressor function","volume":"122","author":"Alarcon-Segovia","year":"1979","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1006\/jaut.1996.0038","article-title":"The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and\/or cell damage","volume":"9","author":"Alarcon-Segovia","year":"1996","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103962_bb0230","first-page":"705","article-title":"Increase of cytokine production by pulmonary artery endothelial cells induced by supernatants from monocytes stimulated with autoantibodies against U1-ribonucleoprotein","volume":"17","author":"Okawa-Takatsuji","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103962_bb0235","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103962_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738473","article-title":"TRIM21\/Ro52 - roles in innate immunity and autoimmune disease","volume":"12","author":"Jones","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0245","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103962_bb0250","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Childhood myositis heterogeneity collaborative study group. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103962_bb0255","doi-asserted-by":"crossref","first-page":"36478","DOI":"10.1074\/jbc.M111.241786","article-title":"Anti-Ro52 autoantibodies from patients with Sjogren\u2019s syndrome inhibit the Ro52 E3 ligase activity by blocking the E3\/E2 interface","volume":"286","author":"Espinosa","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2025.103962_bb0260","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.tibtech.2020.07.003","article-title":"Harnessing SLE autoantibodies for intracellular delivery of biologic therapeutics","volume":"39","author":"Gordon","year":"2021","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.autrev.2025.103962_bb0265","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145875","article-title":"ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody","volume":"6","author":"Rattray","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2025.103962_bb0270","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1002\/eji.200838678","article-title":"Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions","volume":"38","author":"Song","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0275","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103962_bb0280","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103962_bb0285","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103962_bb0290","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103962_bb0295","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1093\/rheumatology\/keaf289","article-title":"Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational study","volume":"64","author":"Kastrati","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103962_bb0300","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jca.21968","article-title":"Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy","volume":"37","author":"Kruse","year":"2022","journal-title":"J Clin Apher"},{"key":"10.1016\/j.autrev.2025.103962_bb0305","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103962_bb0310","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103962_bb0315","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103962_bb0320","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2025.103962_bb0325","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103962_bb0330","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103962_bb0335","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103962_bb0340","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.autrev.2025.103962_bb0345","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103962_bb0350","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217831120","article-title":"Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone","volume":"120","author":"Yogev","year":"2023","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722500223X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722500223X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:05:16Z","timestamp":1770282316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722500223X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S156899722500223X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103962","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibody internalization in myositis skeletal muscle: Emerging evidence, mechanistic insights, and therapeutic relevance","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103962"}}